Effect of beinaglutide, a thrice-daily GLP-1 receptor agonist, on body weight and metabolic parameters: A systematic review and meta-analysis

Table 2 The results of secondary efficacy outcomes findings in the meta-analysis

Outcome variables	No. of RCT included	No. of participants with outcome/participants analyzed		Pooled effect size, OR (95%CI)	I2 (%)	P value
		Beinaglutide arm	Control arm
Categorical
Subjects achieving BW reduction 5%	3	206/335	55/193	4.61 (3.07 to 6.93)	0	< 0.00001
Subjects achieving BW reduction 10%	3	80/335	12/193	5.34 (2.78 to 10.25)	0	< 0.00001
Continuous
SBP (mmHg)	3	349	203	-1.11 (-2.74 to 0.53)	0	0.19
DBP (mmHg)	3	349	203	-0.57 (-1.87 to 0.72)	0	0.38
FPG (mmol/L) in subjects without T2D	3	339	195	-0.11 (-0.26 to 0.04)	43	0.15
FPG (mmol/L) in subjects with T2D	3	107	108	0.32 (-0.50 to 1.15)	63	0.44
HbA1c (%) in subjects with T2D	3	107	108	0.05 (-0.27 to 0.38)	22	0.75
Fasting insulin (mIU/L) in subjects without T2D	2	309	165	-2.28 (-10.97 to 6.41)	69	0.61
HOMA-IR in subjects without T2D	3	339	195	-0.11 (-1.76 to 1.55)	70	0.9
ALT (U/L)	3	99	102	-4.31 (-11.87 to 3.24)	0	0.26
AST (U/L)	3	99	102	-2.65 (-8.11 to 2.81)	41	0.34
TC (mmol/L)	6	446	303	0.18 (-0.41 to 0.76)	95	0.55
LDL-C (mmol/L)	6	446	303	0.17 (-0.41 to 0.75)	99	0.56
HDL-C (mmol/L)	6	446	303	0.18 (-0.36 to 0.71)	99	0.52
TG (mmol/L)	6	446	303	0.16 (-0.43 to 0.75)	94	0.6
FFA (mmol/L)	2	331	190	0.54 (-0.54 to 1.61)	99	0.33

OR: Odds ratio; 95%CI: 95% confidence interval; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; BW: Body weight; FFA: Free fatty acid; FPG: Fasting plasma glucose; HbA1c: Glycated hemoglobin; HDL-C: High-density lipoprotein cholesterol; HOMA-IR: Homeostatic model assessment for insulin resistance; TC: Total cholesterol; RCT: Randomized controlled trials; LDL-C: Low-density lipoprotein cholesterol; TG: Triglyceride; T2D: Type 2 diabetes.